Psychotropic agents in functional gastrointestinal disorders

Madhusudan Grover, Douglas A. Drossman

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established symptom-based criteria. Dysregulation of the brain-gut axis is emerging as the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities. Psychotropic agents act on a variety of neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic, and noradrenergic receptor sites. The role of psychotropic agents, especially tricyclic antidepressants is fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrine reuptake inhibitors is promising. Selective serotonin reuptake inhibitors may provide benefit by reducing symptom anxiety and achieve global symptom relief. In spite of expanding research in evaluating these potential agents, there remains an unmet need in pharmacological management of these disorders, especially at the severe end of their spectrum where options for combined treatments or augmentation need to be developed. In addition, the understanding and management of these disorders hinges on a multidisciplinary biopsychosocial approach, which itself can be a challenging strategy.

Original languageEnglish (US)
Pages (from-to)715-723
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume8
Issue number6
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Gastrointestinal Diseases
Neurotransmitter Receptor
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Brain
Anxiety
Pharmacology
Research

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Psychotropic agents in functional gastrointestinal disorders. / Grover, Madhusudan; Drossman, Douglas A.

In: Current Opinion in Pharmacology, Vol. 8, No. 6, 12.2008, p. 715-723.

Research output: Contribution to journalReview article

@article{13456c8cb2cd458ab5c85cabbef764cc,
title = "Psychotropic agents in functional gastrointestinal disorders",
abstract = "Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established symptom-based criteria. Dysregulation of the brain-gut axis is emerging as the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities. Psychotropic agents act on a variety of neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic, and noradrenergic receptor sites. The role of psychotropic agents, especially tricyclic antidepressants is fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrine reuptake inhibitors is promising. Selective serotonin reuptake inhibitors may provide benefit by reducing symptom anxiety and achieve global symptom relief. In spite of expanding research in evaluating these potential agents, there remains an unmet need in pharmacological management of these disorders, especially at the severe end of their spectrum where options for combined treatments or augmentation need to be developed. In addition, the understanding and management of these disorders hinges on a multidisciplinary biopsychosocial approach, which itself can be a challenging strategy.",
author = "Madhusudan Grover and Drossman, {Douglas A.}",
year = "2008",
month = "12",
doi = "10.1016/j.coph.2008.07.012",
language = "English (US)",
volume = "8",
pages = "715--723",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Psychotropic agents in functional gastrointestinal disorders

AU - Grover, Madhusudan

AU - Drossman, Douglas A.

PY - 2008/12

Y1 - 2008/12

N2 - Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established symptom-based criteria. Dysregulation of the brain-gut axis is emerging as the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities. Psychotropic agents act on a variety of neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic, and noradrenergic receptor sites. The role of psychotropic agents, especially tricyclic antidepressants is fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrine reuptake inhibitors is promising. Selective serotonin reuptake inhibitors may provide benefit by reducing symptom anxiety and achieve global symptom relief. In spite of expanding research in evaluating these potential agents, there remains an unmet need in pharmacological management of these disorders, especially at the severe end of their spectrum where options for combined treatments or augmentation need to be developed. In addition, the understanding and management of these disorders hinges on a multidisciplinary biopsychosocial approach, which itself can be a challenging strategy.

AB - Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established symptom-based criteria. Dysregulation of the brain-gut axis is emerging as the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities. Psychotropic agents act on a variety of neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic, and noradrenergic receptor sites. The role of psychotropic agents, especially tricyclic antidepressants is fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrine reuptake inhibitors is promising. Selective serotonin reuptake inhibitors may provide benefit by reducing symptom anxiety and achieve global symptom relief. In spite of expanding research in evaluating these potential agents, there remains an unmet need in pharmacological management of these disorders, especially at the severe end of their spectrum where options for combined treatments or augmentation need to be developed. In addition, the understanding and management of these disorders hinges on a multidisciplinary biopsychosocial approach, which itself can be a challenging strategy.

UR - http://www.scopus.com/inward/record.url?scp=55649116852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649116852&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2008.07.012

DO - 10.1016/j.coph.2008.07.012

M3 - Review article

C2 - 18760380

AN - SCOPUS:55649116852

VL - 8

SP - 715

EP - 723

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 6

ER -